Portola Pharmaceuticals Lands $89,000,000 New Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=6ac03b1c-098a-47a7-8e94-aeb73af81b90&Preview=1 -
Date
11/22/2011 -
Company Name
Portola Pharmaceuticals -
Mailing Address
270 E. Grand Avenue South San Francisco, CA 94080 -
Company Description
Portola Pharmaceuticals, Inc. is a private biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascular disease. Portola has two drug candidates in clinical development. The most advanced compound is an oral Factor Xa inhibitor that is entering a Phase II trial for the prevention of DVT in patients undergoing knee surgery. -
Website
http://www.portola.com -
Transaction Type
Venture Equity -
Transaction Amount
$89,000,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
Proceeds will be used primarily to advance betrixaban, a once-daily, oral Factor Xa inhibitor, through Phase 3 clinical development and to advance development of its companion product, PRT064445, a recombinant Factor Xa inhibitor antidote designed to reverse anticoagulant activity in patients treated with Factor Xa inhibitors suffering major bleeds or requiring surgery. Portola plans to initiate a Phase 3 betrixaban program to prevent venous thromboembolism (VTE) in acute medically ill patients in the first half of 2012. -
M&A Terms
-
Venture Investor
Temasek Holdings -
Venture Investor
Undisclosed
